Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
pharmaceutical investing Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
pharmaceutical investing Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346
Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346
pharmaceutical investing Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Homerun Resources Inc. Announces Receipt of a Competitive Budgetary Offer for Latin America's First Dedicated Solar Glass Manufacturing Facility
